275 related articles for article (PubMed ID: 15862515)
21. Involvement of presynaptic 5-HT
Mombereau C; Arnt J; Mørk A
Pharmacol Biochem Behav; 2017 Feb; 153():141-146. PubMed ID: 28057524
[TBL] [Abstract][Full Text] [Related]
22. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Egashira N; Okuno R; Matsushita M; Abe M; Mishima K; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
Eur J Pharmacol; 2008 Sep; 592(1-3):103-8. PubMed ID: 18644366
[TBL] [Abstract][Full Text] [Related]
23. Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.
Lemoine L; Becker G; Vacher B; Billard T; Lancelot S; Newman-Tancredi A; Zimmer L
J Nucl Med; 2012 Jun; 53(6):969-76. PubMed ID: 22577236
[TBL] [Abstract][Full Text] [Related]
24. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
[TBL] [Abstract][Full Text] [Related]
25. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
[TBL] [Abstract][Full Text] [Related]
26. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
27. Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice.
Scorza MC; Castañé A; Bortolozzi A; Artigas F
Neuropharmacology; 2010; 59(1-2):112-20. PubMed ID: 20412811
[TBL] [Abstract][Full Text] [Related]
28. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders.
Shimizu S; Tatara A; Imaki J; Ohno Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):877-81. PubMed ID: 20398719
[TBL] [Abstract][Full Text] [Related]
29. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
[TBL] [Abstract][Full Text] [Related]
31. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
Newman-Tancredi A; Rivet JM; Cussac D; Touzard M; Chaput C; Marini L; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):188-99. PubMed ID: 12923612
[TBL] [Abstract][Full Text] [Related]
33. The influence of repeated administration of clozapine and haloperidol on the effects of the activation of 5-HT(1A), 5-HT(2) and 5-HT(4) receptors in rat frontal cortex.
Zahorodna A; Bobula B; Grzegorzewska M; Tokarski K; Hess G
J Physiol Pharmacol; 2004 Jun; 55(2):371-9. PubMed ID: 15213359
[TBL] [Abstract][Full Text] [Related]
34. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
35. Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone.
Frankle WG; Lombardo I; Kegeles LS; Slifstein M; Martin JH; Huang Y; Hwang DR; Reich E; Cangiano C; Gil R; Abi-Dargham A; Laruelle M
J Psychopharmacol; 2011 Jun; 25(6):734-43. PubMed ID: 21109614
[TBL] [Abstract][Full Text] [Related]
36. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes.
Czyrak A; Skuza G; Rogóz Z; Frankiewicz T; Maj J
Arzneimittelforschung; 1994 Feb; 44(2):113-8. PubMed ID: 7511901
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Holthoewer D; Kirschbaum KM; Frisch J; Hiemke C; Schmitt U
Pharmacopsychiatry; 2013 Jul; 46(5):175-80. PubMed ID: 23737243
[TBL] [Abstract][Full Text] [Related]
39. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
Gogos A; Bogeski M; van den Buuse M
Behav Pharmacol; 2008 Sep; 19(5-6):548-61. PubMed ID: 18690109
[TBL] [Abstract][Full Text] [Related]
40. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
